

Grifols and Laboratorios Divasa sign a strategic cooperation agreement

Laboratorios Grifols will manufacture Laboratorios Divasa Farmavic's new fluid therapy line for the veterinary market.

Barcelona, 22 October 2007: Laboratorios Grifols, Spain's leading fluid therapy producer, and Laboratorios Divasa, a key player in the animal health sector, have signed a strategic cooperation agreement under which Laboratorios Grifols will manufacture a line of fluid therapy products for veterinary use. Laboratorios Divasa will be responsible for the products' commercial distribution and will own the licences.

The agreement between both companies will make Grifols' extensive experience as a manufacturer of fluid therapy for human use available to the veterinary market, while also drawing on Divasa Farmavic's thorough knowledge of the specific requirements of the animal health market.

The new veterinary fluid therapy line, consisting of a range of products, will benefit from the innovative packaging of solutions in the Flebobag®, usually used in the hospital sector for its ease of handling, its complete transparency which allows the solution to be seen clearly, and its guarantee of the sterility of the outside of the packaging thanks to its double protective bag.

About Grifols

Grifols is a Spanish holding company specialized in the hospital-pharmaceutical sector, it is the world's fourth-largest producer of plasma products and has a presence in more than 90 countries. It researches, develops, manufactures and distributes plasma products and products for intravenous therapy, diagnostic systems and medical supplies. It has been listed on Spain's Mercado Continuo since May 2006 and is included in the Spanish index of medium capitalized companies (IBEX MEDIUM CAP).

About Divasa Farmavic (DFV®)

Divasa Farmavic is a leader in the animal health sector. It has one of Europe's most advanced veterinary medicine manufacturing plants, and its products are sold in over 50 countries. It is one of the most active companies in the pets sector, at which this new business line is primarily aimed.